Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2019 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
February 11, 2019 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility

NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
January 03, 2019 01:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™

NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
January 02, 2019 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
December 03, 2018 08:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer

-Potential to Improve Early Detection and Transform the Treatment Landscape for Recurrent Prostate Cancer - NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc....
November 19, 2018 16:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting

NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
November 08, 2018 07:30 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA)AZEDRA U.S. Launch Progressing and AZEDRA Added to the NCCN Guidelines and Four CMS-Recognized Drug CompendiaPhase 3 Study...
November 06, 2018 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals to Present at Upcoming Investor Conferences

NEW YORK, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
November 01, 2018 08:00 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8

NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and...
October 11, 2018 16:01 ET | Source: Progenics Pharmaceuticals Inc.

Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA

– Trial will utilize PyL imaging in order to target the patients most likely to benefit, advancing the Company’s theranostic approach to the treatment of prostate cancer – NEW YORK, Oct. 11, 2018 ...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right